AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
View PDF
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA

Kenan Zhang1Xing Liu2Guanzhang Li1,3Xin Chang4Shouwei Li4Jing Chen1Zheng Zhao1Jiguang Wang5,6,7Tao Jiang1,3 ( )Ruichao Chai1,2,5( )
Department of Molecular Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China
Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China
Division of Life Science and State Key Laboratory of Molecular Neuroscience, Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR 999077, China
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong SAR 999077, China
HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute, Futian, Shenzhen 518057, China
Show Author Information

Abstract

Objective

We aimed to summarize the clinicopathological characteristics and prognostic features of various molecular subtypes of diffuse gliomas (DGs) in the Chinese population.

Methods

In total, 1,418 patients diagnosed with DG between 2011 and 2017 were classified into 5 molecular subtypes according to the 2016 WHO classification of central nervous system tumors. The IDH mutation status was determined by immunohistochemistry and/or DNA sequencing, and 1p/19q codeletion was detected with fluorescence in situ hybridization. The median clinical follow-up time was 1,076 days. T-tests and chi-square tests were used to compare clinicopathological characteristics. Kaplan-Meier and Cox regression methods were used to evaluate prognostic factors.

Results

Our cohort included 15.5% lower-grade gliomas, IDH-mutant and 1p/19q-codeleted (LGG-IDHm-1p/19q); 18.1% lower-grade gliomas, IDH-mutant (LGG-IDHm); 13.1% lower-grade gliomas, IDH-wildtype (LGG-IDHwt); 36.1% glioblastoma, IDH-wildtype (GBM-IDHwt); and 17.2% glioblastoma, IDH-mutant (GBM-IDHm). Approximately 63.3% of the enrolled primary gliomas, and the median overall survival times for LGG-IDHm, LGG-IDHwt, GBM-IDHwt, and GBM-IDHm subtypes were 75.97, 34.47, 11.57, and 15.17 months, respectively. The 5-year survival rate of LGG-IDHm-1p/19q was 76.54%. We observed a significant association between high resection rate and favorable survival outcomes across all subtypes of primary tumors. We also observed a significant role of chemotherapy in prolonging overall survival for GBM-IDHwt and GBM-IDHm, and in prolonging post-relapse survival for the 2 recurrent GBM subtypes.

Conclusions

By controlling for molecular subtypes, we found that resection rate and chemotherapy were 2 prognostic factors associated with survival outcomes in a Chinese cohort with DG.

Electronic Supplementary Material

Download File(s)
cbm-19-10-1460_ESM.pdf (237.4 KB)

References

1

Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23: iii1-iii105.

2

Jiang T, Nam DH, Ram Z, Poon WS, Wang J, Boldbaatar D, et al. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2021; 499: 60-72.

3

Jiang T, Tang GF, Lin Y, Peng XX, Zhang X, Zhai XW, et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J (Engl). 2011; 124: 2578-83.

4

Liu J, Li C, Wang Y, Ji P, Guo S, Zhai Y, et al. Prognostic and predictive factors in elderly patients with glioblastoma: a single-center retrospective study. Front Aging Neurosci. 2021; 13: 777962.

5

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022; 2: 1-9.

6

Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013; 113: 259-66.

7

Xu YY, Gao P, Sun Y, Duan YR. Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med. 2015; 12: 223-37.

8

Chai RC, Liu YQ, Zhang KN, Wu F, Zhao Z, Wang KY, et al. A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. Mod Pathol. 2019; 32: 4-15.

9

Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, et al. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med. 2021; 18: 272-82.

10

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-73.

11

Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010; 74: 1886-90.

12

Xie Y, Tan Y, Yang C, Zhang X, Xu C, Qiao X, et al. Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis. Cancer Biol Med. 2019; 16: 784-96.

13

Louis DN, Perry A, Reifenberger G, von Deimling A, FigarellaBranger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131: 803-20.

14

Chai RC, Li YM, Zhang KN, Chang YZ, Liu YQ, Zhao Z, et al. RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. JCI Insight. 2019; 5.

15

Chai RC, Chang YZ, Chang X, Pang B, An SY, Zhang KN, et al. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-kB and promote the malignant progression of glioma. J Hematol Oncol. 2021; 14: 109.

16

Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol. 2017; 134: 505-12.

17

Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018; 44: 139-50.

18

Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, et al. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Carcinogenesis. 2019; 40: 1229-39.

19

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015; 372: 2499-508.

20

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, et al. Chemotherapy for adult low-grade gliomas: Clinical outcomes by molecular subtype in a phase Ⅱ study of adjuvant temozolomide. Neuro Oncol. 2017; 19: 242-51.

21

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase Ⅲ trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013; 31: 337-43.

22

Ding X, Wang Z, Chen D, Wang Y, Zhao Z, Sun C, et al. The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. J Neurooncol. 2018; 140: 591-603.

23

Jakola AS, Pedersen LK, Skjulsvik AJ, Myrmel K, Sjavik K, Solheim O. The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study. J Neurosurg. 2022; 1-8.

24

Hou Z, Zhang K, Liu X, Fang S, Li L, Wang Y, et al. Molecular subtype impacts surgical resection in low-grade gliomas: a Chinese glioma genome atlas database analysis. Cancer Lett. 2021; 522: 14-21.

25

Li SW, Qiu XG, Chen BS, Zhang W, Ren H, Wang ZC, et al. Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J (Engl). 2009; 122: 1245-9.

26

Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, et al. Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from chinese glioma patients. Genom Proteom Bioinform. 2021; 19: 1-12.

27

Chai RC, Zhang KN, Liu YQ, Wu F, Zhao Z, Wang KY, et al. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. CNS Neurosci Ther. 2019; 25: 314-22.

28

Orringer D, Lau D, Khatri S, Zamora-Berridi GJ, Zhang K, Wu C, et al. Extent of resection in patients with glioblastoma: Limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012; 117: 851-9.

29

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021; 18: 170-86.

30

Mijderwijk HJ, Nieboer D, Incekara F, Berger K, Steyerberg EW, van den Bent MJ, et al. Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. J Neurosurg. 2022; 1-10.

31

Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18: 1537-70.

32

Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018; 392: 432-46.

33

Rossi M, Gay L, Ambrogi F, Conti Nibali M, Sciortino T, Puglisi G, et al. Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol. 2021; 23: 812-26.

34

Mair MJ, Geurts M, van den Bent MJ, Berghoff AS. A basic review on systemic treatment options in WHO grade Ⅱ-Ⅲ gliomas. Cancer Treat Rev. 2021; 92: 102124.

35

Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020; 70: 299-312.

36

Stoyanov GS, Lyutfi E, Georgieva R, Georgiev R, Dzhenkov DL, Petkova L, et al. Reclassification of glioblastoma multiforme according to the 2021 World Health Organization classification of central nervous system tumors: a single institution report and practical significance. Cureus. 2022; 14: e21822.

37

Mizoguchi M, Hata N, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, et al. Clinical implications of molecular analysis in diffuse glioma stratification. Brain Tumor Pathol. 2021; 38: 210-7.

38

Ostrom QT, Shoaf ML, Cioffi G, Waite K, Kruchko C, Wen PY, et al. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol. 2022; noac198.

39

Brown NF, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S, et al. Survival outcomes and prognostic factors in glioblastoma. Cancers (Basel). 2022; 14: 3161.

40

Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 2016; 130: 269-82.

41

Karschnia P, Vogelbaum MA, van den Bent M, Cahill DP, Bello L, Narita Y, et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021; 149: 23-33.

42

Albuquerque LAF, Almeida JP, de Macedo Filho LJM, Joaquim AF, Duffau H. Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature – a systematic review of the literature. Neurosurg Rev. 2021; 44: 1371-89.

43

Still MEH, Roux A, Huberfeld G, Bauchet L, Baron MH, Fontaine D, et al. Extent of resection and residual tumor thresholds for postoperative total seizure freedom in epileptic adult patients harboring a supratentorial diffuse low-grade glioma. Neurosurgery. 2019; 85: E332-40.

44

Robe PA, Rados M, Spliet WG, Hoff RG, Gosselaar P, Broekman MLD, et al. Early surgery prolongs professional activity in IDH mutant low-grade glioma patients: a policy change analysis. Front Oncol. 2022; 12: 851803.

45

Mladenovsk M, Valkov I, Ovcharov M, Vasilev N, Duhlenski I. High grade glioma surgery – clinical aspects and prognosis. Folia Med (Plovdiv). 2021; 63: 35-41.

46

Hollon T, Hervey-Jumper SL, Sagher O, Orringer DA. Advances in the surgical management of low-grade glioma. Semin Radiat Oncol. 2015; 25: 181-8.

47

Mirza FA, Shamim MS. Extent of resection and timing of surgery in adult low grade glioma. J Pak Med Assoc. 2017; 67: 959-61.

48

Gutman DC, Young RJ. IDH glioma radiogenomics in the era of deep learning. Neuro Oncol. 2021; 23: 182-3.

49

Singh G, Manjila S, Sakla N, True A, Wardeh AH, Beig N, et al. Radiomics and radiogenomics in gliomas: a contemporary update. Br J Cancer. 2021; 125: 641-57.

50

Kazerooni AF, Bakas S, Rad HS, Davatzikos C. Imaging signatures of glioblastoma molecular characteristics: a radiogenomics review. J Magn Reson Imaging. 2020; 52: 54-69.

51

Li Y, Qian Z, Xu K, Wang K, Fan X, Li S, et al. MRI features predict p53 status in lower-grade gliomas via a machine-learning approach. Neuroimage Clin. 2018; 17: 306-11.

52

Fang S, Liang Y, Li L, Wang L, Fan X, Wang Y, et al. Tumor location-based classification of surgery-related language impairments in patients with glioma. J Neurooncol. 2021; 155: 143-52.

53

Liu X, Li Y, Li S, Fan X, Sun Z, Yang Z, et al. IDH mutation-specific radiomic signature in lower-grade gliomas. Aging (Albany NY). 2019; 11: 673-96.

54

Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021; 23: 1872-84.

55

Gramatzki D, Felsberg J, Roth P, Kaulich K, von Deimling A, Rushing EJ, et al. The molecular evolution of glioblastoma treated by gross total resection alone. Neuro Oncol. 2021; 23: 334-6.

56

Tavelin B, Malmstrom A. Sex differences in glioblastoma-findings from the swedish national quality registry for primary brain tumors between 1999-2018. J Clin Med. 2022; 11: 486.

57

Moore KJ, Moertel CL, Williams LA. Young adult males have worse survival than females that is largely independent of treatment received for many types of central nervous system tumors: a National Cancer Database Analysis. Cancer. 2022; 128: 1616-25.

58

Wang GM, Cioffi G, Patil N, Waite KA, Lanese R, Ostrom QT, et al. Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro Oncol. 2022; 24: 302-10.

59

Alexopoulos G, Zhang J, Karampelas I, Patel M, Kemp J, Coppens J, et al. Long-term time series forecasting and updates on survival analysis of glioblastoma multiforme: a 1975-2018 population-based study. Neuroepidemiology. 2022; 56: 75-89.

60

Hirtz A, Rech F, Dubois-Pot-Schneider H, Dumond H. Astrocytoma: a hormone-sensitive tumor? Int J Mol Sci. 2020; 21: 9114.

61

Eldesouki S, Samara KA, Qadri R, Obaideen AA, Otour AH, Habbal O, et al. XIST in brain cancer. Clin Chim Acta. 2022; 531: 283-90.

62

Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, et al. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 2018; 135: 481-4.

63

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23: 1231-51.

64

Huang LE. Impact of CDKN2A/B homozygous deletion on the prognosis and biology of IDH-mutant glioma. Biomedicines. 2022; 10: 246.

65

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018; 20: 66-77.

Cancer Biology & Medicine
Pages 1460-1476
Cite this article:
Zhang K, Liu X, Li G, et al. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA. Cancer Biology & Medicine, 2022, 19(10): 1460-1476. https://doi.org/10.20892/j.issn.2095-3941.2022.0469

34

Views

1

Downloads

24

Crossref

19

Web of Science

21

Scopus

Altmetrics

Received: 05 August 2022
Accepted: 05 September 2022
Published: 03 November 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License

Return